KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EPS (Weighted Average and Diluted) (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed 0.0% to $0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.09 through Dec 2025, up 80.0% year-over-year, with the annual reading at $0.09 for FY2025, 125.0% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.02 in Q4 2025 for GoodRx Holdings, up from $0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.14 in Q2 2023 to a low of -$0.1 in Q3 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.0 across 5 years, with a median of $0.0 in 2025.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 4177.66% in 2023; the steepest drop was 500.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.09 in 2021, then soared by 88.89% to -$0.01 in 2022, then plummeted by 500.0% to -$0.06 in 2023, then soared by 133.33% to $0.02 in 2024, then decreased by 0.0% to $0.02 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GDRX at $0.02 in Q4 2025, $0.0 in Q3 2025, and $0.04 in Q2 2025.